Testing
Temporal changes in lipoprotein(a) following acute coronary syndrome show significant increases weeks to months later (Eur J Prev Cardiol 2026)
Original title: Temporal Changes in Lipoprotein(a) Following Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis of 16 studies comprising 1,396 patients evaluated serial lipoprotein(a) measurements after acute coronary syndrome. Pooled percent change in mean lipoprotein(a) was non-significant at 24 hours (+2.5%, 95% CI -6.8 to 11.7; p=0.602) but significantly elevated at 7-14 days (+44.0%, 95% CI 4.0-84.1; p=0.031), 1 month (+28.3%, 95% CI 2.7-54.0; p=0.030), and 3-6 months (+22.2%, 95% CI 2.4-42.0; p=0.028). Absolute increases exceeding 25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively. Early post-event testing may underestimate long-term concentrations and should be repeated weeks to months later when values approach clinical decision thresholds.
Original abstract
Aims: Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor generally considered stable over an individual's lifetime. Acute coronary syndrome (ACS) may transiently alter Lp(a) concentrations, complicating interpretation. We systematically evaluated temporal changes in Lp(a) following ACS.
Methods: This PRISMA 2020-guided systematic review searched MEDLINE and Embase from database inception to February 2026. Eligible studies reported serial Lp(a) measurements at two or more time points after index ACS event. Exploratory random-effects meta-analysis of percent change in mean Lp(a) was performed.
Results: Of 3,811 records, 16 studies comprising 1,396 patients met inclusion criteria. Lp(a) demonstrated a dynamic post-ACS trajectory. Using initial post-ACS measurements as the reference, pooled percent change in mean Lp(a) was non-significant at 24 hours post-ACS (+2.5%, 95% CI -6.8 to 11.7; p=0.602). Lp(a) was significantly higher at 7-14 days (+44.0%, 95% CI 4.0-84.1; p=0.031), 1 month (+28.3%, 95% CI 2.7-54.0; p=0.030), and 3-6 months (+22.2%, 95% CI 2.4-42.0; p=0.028). Across two studies, absolute Lp(a) increases >25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively.
Conclusions: Lp(a) is not static post-ACS. Early post-ACS measurements may underestimate long-term concentrations and risk. Repeat measurement weeks to months later is most informative when initial post-ACS Lp(a) values are near clinical decision thresholds or would influence eligibility for emerging Lp(a)-lowering therapies.
epidemiologyinflammationrisktesting
Summary written by lp-a.org from the published abstract; figures as published. Page updated 14 November 2026. Methods.